Sulfur Burps on Wegovy (Semaglutide 2.4 mg): Incidence, Severity, and Realistic Expectations

At a glance

• Reported incidence (eructation, all grades): ~1 to 3% in the STEP 1 trial, compared with <1% on placebo
• Typical onset: Weeks 1 through 8, aligning with the 16-week dose-escalation schedule
• Peak severity window: Usually during or just after each dose increase (0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg)
• First-line management: Dietary sulfur reduction, smaller meals, simethicone or bismuth subsalicylate
• When to escalate: If burps persist daily beyond 6 weeks at a stable dose, or are accompanied by vomiting, severe abdominal pain, or weight loss stalling
• When to consider discontinuation: Rarely necessary for eructation alone; discuss with prescriber if co-occurring gastroparesis symptoms (early satiety, nausea lasting >72 hours, inability to maintain hydration) fail conservative management

What Sulfur Burps Actually Are

Sulfur burps are episodes of eructation carrying a hydrogen sulfide (H₂S) odor, commonly described as smelling like rotten eggs. The gas itself is produced when gut bacteria ferment sulfur-containing amino acids (cysteine, methionine) and certain food additives. Under normal digestive transit, most of this fermentation occurs in the colon. On semaglutide, the process shifts.

Semaglutide slows gastric emptying by activating GLP-1 receptors on vagal afferent neurons and enteric smooth muscle. Food stays in the stomach and proximal small intestine longer than usual. Sulfur-containing foods that would normally move past the upper GI tract in 2 to 4 hours may sit for 6 hours or more. That extended dwell time gives bacteria additional time to produce H₂S, which then exits via the esophagus as a sulfur-tasting belch.

This mechanism is not unique to Wegovy. It has been observed across the GLP-1 receptor agonist class, including liraglutide and tirzepatide, though the degree of gastric slowing varies by agent and dose.

What the Trial Data Actually Shows

The key STEP 1 trial (n=1,961) reported gastrointestinal adverse events in 74.2% of the semaglutide 2.4 mg group versus 47.9% on placebo. The protocol classified belching under "eructation" without distinguishing sulfur-flavored episodes from ordinary burps. Eructation appeared in approximately 1 to 3% of the active arm.

Across STEP 2 (participants with type 2 diabetes) and STEP 3 (intensive behavioral therapy), eructation rates were similar. "Dyspepsia," which can include sulfur burps reported as stomach upset, was documented in 3 to 5% of participants on the 2.4 mg dose.

A few things are worth noting about these numbers. Clinical trials use MedDRA-coded adverse event terms, and "sulfur burps" is not a MedDRA term. Patients reporting rotten-egg belching may have been coded as eructation, dyspepsia, or flatulence depending on how site investigators interpreted the complaint. The true prevalence of specifically sulfur-flavored burps is almost certainly higher than the eructation line item alone suggests.

Post-marketing pharmacovigilance data and large-cohort real-world studies (including a 2023 analysis of FDA Adverse Event Reporting System data) show eructation among the more commonly self-reported GI side effects for semaglutide products, though still well behind nausea, diarrhea, and constipation.

Severity Distribution: Most Cases Are Mild

In the STEP program, GI adverse events were graded by the Common Terminology Criteria for Adverse Events (CTCAE). For eructation specifically:

• Grade 1 (mild): Occasional episodes, no dietary modification required. This accounts for the majority of reported cases.
• Grade 2 (moderate): Frequent episodes that interfere with meals or social situations. A smaller subset, typically during rapid dose escalation.
• Grade 3+ (severe): Persistent eructation requiring medical intervention or causing dehydration. Extremely rare for isolated burping; when grade 3 GI events occurred in STEP trials, they almost always involved nausea or vomiting rather than eructation alone.

Discontinuation rates due to GI events were 4.5% in the semaglutide arm of STEP 1. Eructation alone was not a significant driver of discontinuation in any STEP trial.

Who Tends to Get Sulfur Burps

No demographic subgroup analysis from the STEP program specifically isolates eructation risk. However, several clinical patterns emerge from the trial data and prescribing experience documented in GLP-1 management literature:

Higher-risk profiles:

• Patients with pre-existing functional dyspepsia or gastroesophageal reflux. Baseline dysmotility compounds the gastric-emptying delay from semaglutide.
• Diets rich in cruciferous vegetables (broccoli, cauliflower, cabbage), alliums (garlic, onions), eggs, and red meat. These foods have high sulfur amino acid content.
• Patients on proton pump inhibitors (PPIs). Reduced gastric acid may alter bacterial populations in the upper GI tract, potentially increasing H₂S production.
• Those escalating doses rapidly or not following the recommended 16-week escalation schedule.

Lower-risk profiles:

• Patients who have already tolerated other GLP-1 agonists at therapeutic doses.
• Those following a lower-sulfur, higher-fiber diet before starting treatment.

Timeline: When It Starts and When It Stops

The typical pattern follows a predictable curve tied to dose escalation:

Weeks 1 to 4 (0.25 mg): Some patients notice mild eructation, but sulfur burps at this dose are uncommon. Gastric emptying is only modestly delayed.

Weeks 5 to 12 (0.5 mg to 1.0 mg): This is when most sulfur burp complaints begin. The magnitude of gastric slowing increases meaningfully at these doses. Patients eating the same diet they ate before treatment now retain food in the stomach substantially longer.

Weeks 13 to 16 (1.7 mg to 2.4 mg): Peak incidence. Some patients experience daily sulfur burps at these dose steps. The GI tract has not yet fully adapted to the maximum degree of delayed emptying.

Weeks 17 to 24 (maintenance at 2.4 mg): Gradual improvement for most. The enteric nervous system partially adapts to sustained GLP-1 receptor activation, and patients typically learn to modify their diets. Most patients who had sulfur burps during escalation report a significant reduction by week 20 to 24.

Beyond 6 months: Persistent daily sulfur burps at this point are unusual and warrant clinical reassessment, including evaluation for gastroparesis, small intestinal bacterial overgrowth (SIBO), or Helicobacter pylori infection.

Practical Management

The Wegovy prescribing information recommends general GI symptom management but does not address sulfur burps directly. The following approaches are supported by gastroenterology consensus and clinical practice:

Dietary modifications (first-line):

• Reduce intake of high-sulfur foods: eggs, garlic, onions, cruciferous vegetables, dried fruit preserved with sulfites, beer, and wine.
• Eat smaller, more frequent meals. A stomach that is already slow to empty handles 300-calorie meals far better than 800-calorie ones.
• Avoid carbonated beverages, which add exogenous gas to an already-distended stomach.

Over-the-counter options:

• Bismuth subsalicylate (Pepto-Bismol) binds H₂S in the gut and can reduce sulfur odor. Standard dosing: 262 mg to 524 mg as needed, up to 8 doses per day. Not for long-term daily use.
• Simethicone (Gas-X) may reduce bloating but does not specifically neutralize H₂S. Some patients find it helpful for associated pressure.

Prescription considerations:

• Prokinetic agents (metoclopramide, domperidone) are occasionally used when sulfur burps co-occur with significant nausea and vomiting, but carry their own side-effect profiles and are not first-line for eructation alone.
• Extended dose escalation (spending 4 weeks at each step instead of the standard schedule) can reduce GI side-effect severity, as noted in AGA clinical guidance on GLP-1 GI management.

When to Contact Your Prescriber

Sulfur burps alone are unpleasant but not dangerous. However, contact your prescriber if any of the following apply:

• Burps are accompanied by vomiting that lasts more than 48 hours
• You are unable to keep liquids down
• Abdominal pain is severe or localized to one area
• You notice unintentional weight loss beyond what is expected from Wegovy treatment
• Symptoms worsen rather than improve after 6 or more weeks at a stable dose
• You develop new symptoms such as foul-smelling stool, diarrhea, or fever (which may suggest SIBO or infection rather than simple fermentation)

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183

2. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. doi:10.1016/S0140-6736(21)00213-0

3. Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity (STEP 3). JAMA. 2021;325(14):1403-1413. doi:10.1001/jama.2021.1831

4. Novo Nordisk. Wegovy (semaglutide) prescribing information. U.S. Food and Drug Administration. 2021. FDA label

5. Camilleri M. Clinical practice: gastroparesis. N Engl J Med. 2004;356(22):2106-2115. Gastroenterology reference

6. American Gastroenterological Association. Clinical guidance on GLP-1 receptor agonist gastrointestinal side-effect management. Gastroenterology. 2024. AGA guidance

7. Chey WD, Howden CW, Moss SF, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2024. ACG guideline